View Older Stories View More Recent Stories

Oct 12, 2021 01:30AM OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
Oct 11, 2021 01:30AM OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
Oct 11, 2021 01:30AM OSE Immunotherapeutics Receives New European Patent Notice of Allowance for Tedopi®
Sep 30, 2021 12:30PM Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezaben
Sep 30, 2021 12:30PM Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in Phase 1 Expansion Trial of SIRPα Antagonist Monoclonal Antibody BI 765063 in combination with anti-PD-1 Antibody Ezaben
Sep 27, 2021 12:00PM OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
Sep 27, 2021 12:00PM OSE Immunotherapeutics to Host an “Immuno-Oncology R&D Day” On October 12th, 2021
Sep 21, 2021 12:19PM OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
Sep 21, 2021 12:00PM OSE Immunotherapeutics Announces H1 2021 Results and Provides a Corporate Update
Sep 20, 2021 07:45AM OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO
Sep 20, 2021 07:45AM OSE Immunotherapeutics Presented Positive Final Results of Tedopi® Phase 3 Clinical Trial in Secondary Resistant Non-Small Cell Lung Cancer Patients at the European Society for Medical Oncology (ESMO
Sep 20, 2021 01:30AM OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors At the European Soc
Sep 20, 2021 01:30AM OSE Immunotherapeutics To Present Positive Results of Tedopi® Phase 3 Clinical Trial in Non-Small Cell Lung Cancer Patients in Secondary Resistance to Immune Checkpoint Inhibitors
Sep 16, 2021 12:12PM Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
Sep 16, 2021 12:00PM Boehringer Ingelheim and OSE Immunotherapeutics Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
Sep 13, 2021 01:30AM Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
Sep 13, 2021 01:30AM Boehringer Ingelheim and OSE Immunotherapeutics to Present Phase 1 Results with First-in-Class SIRPα Inhibitor BI 765063 in Advanced Solid Tumors at ESMO 2021
Sep 7, 2021 01:30AM OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
Sep 7, 2021 01:30AM OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®
Sep 1, 2021 12:00PM OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Sep 1, 2021 12:00PM OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Aug 26, 2021 12:00PM OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Aug 26, 2021 12:00PM OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer
Aug 25, 2021 12:01PM Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
Aug 25, 2021 12:00PM Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome
Aug 24, 2021 12:00PM OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day
Aug 24, 2021 12:00PM OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day
Jul 19, 2021 12:00PM OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
Jul 19, 2021 12:00PM OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study
Jul 9, 2021 12:00PM OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
Jul 9, 2021 12:00PM OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank
Jun 30, 2021 01:30AM OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
Jun 30, 2021 01:30AM OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine
Jun 24, 2021 12:00PM OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
Jun 24, 2021 12:00PM OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting
Jun 3, 2021 12:00PM OSE Immunotherapeutics Announces Procedures for Virtual Combined General Meeting
May 27, 2021 12:08PM OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
May 27, 2021 12:00PM OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer
May 26, 2021 01:30AM OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
May 26, 2021 01:30AM OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
May 20, 2021 01:30AM OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
May 20, 2021 01:30AM OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
May 18, 2021 01:30AM OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1
May 18, 2021 01:30AM OSE Immunotherapeutics Announces €10.7 Million in Additional Public Funding, via Bpifrance, to Finance Further Development of CoVepiT, its Multi-Target and Multi-Variant COVID-19 Vaccine in Phase 1
Apr 26, 2021 12:00PM OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market
Apr 26, 2021 12:00PM OSE Immunotherapeutics and Veloxis Pharmaceuticals Enter Into Global License Agreement to Develop, Manufacture, and Commercialize FR104, a CD28 Antagonist, in the Organ Transplantation Market
Apr 6, 2021 01:30AM OSE Immunotherapeutics Announces First Peer-Reviewed Publication in Science Advances on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
Apr 6, 2021 01:30AM OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation
Apr 1, 2021 12:00PM OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
Apr 1, 2021 12:00PM OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine
View More Recent Stories View Older Stories